Breaking News Instant updates and real-time market news.

AMZN

Amazon.com

$1,129.13

-3.75 (-0.33%)

, BAX

Baxter

$63.46

-1.935 (-2.96%)

11:59
11/10/17
11/10
11:59
11/10/17
11:59

Med tech stocks dip as Citi raises specter of Amazon competition

Shares of medical technology companies are trading lower after a Citi analyst said that Amazon (AMZN) is coming for the medical technology sector "sooner than you think." AMAZON EFFORTS IN MEDICAL SUPPLIES: Citi analyst Amit Hazan said in a research note that Amazon is likely further ahead in accessing the medical supply chain than it is within other parts of healthcare, such as pharmaceuticals. The analyst believes that the company is working with an advisory board of "at least" 12 big hospital systems who in total represent 5%-8% of supply purchases in the U.S., and forecasts a high likelihood that one or more major hospital systems could announce the e-commerce giant as their distributor in the near term. Hazan added that hospital systems his firm spoke to were "overwhelmingly positive" towards an Amazon entry, with "a number of entities" estimating that 20%-30% of their medical supply purchases could move to Amazon distribution within the next two years. SHORT TERM, MEDIUM TERM VIEWS: Hazan said that, in the near-term, his firm does not see much of a fundamental risk for the medical device sector from an Amazon entry, though in the medium-term he sees a high probability of a major dislocation of both distributors and Group Purchasing Organizations, or GPOs. This in turn will likely result in incremental pricing pressure for the medical device sector. In addition, the analyst believes that, in the medium to long term, GPOs will likely no longer be a part of the contracting process, and that new online distribution and wholesaling models, such as Amazon's, will come to dominate the supply chain. RISKS/OPPORTUNITIES: The Citi analyst noted that key risks to the medical device sector include greater price transparency, greater competitive threats from smaller players, and more efficiency at the provider site. Hazan added that manufacturers may also see certain opportunities to significantly cut costs related to contracting and logistics, significant potential first-mover opportunities for those who embrace the change, and opportunities for expanded reach at attractive operating costs. Despite all of these forecasts, Hazan said that, on a stock specific basis, it is too early to tell which companies are most exposed in either direction and by how much. PRICE ACTION: Near midday, medical device makers Baxter (BAX), Becton Dickinson (BDX), Boston Scientific (BSX), Medtronic (MDT), Stryker (SYK) and Zimmer Biomet (ZBH) were all down at least 1.6%, while healthcare distributors Cardinal Health (CAH) and McKesson (MCK) are also trading lower. AmerisourceBergen (ABC), on the other hand, is up marginally.

AMZN

Amazon.com

$1,129.13

-3.75 (-0.33%)

BAX

Baxter

$63.46

-1.935 (-2.96%)

BDX

Becton Dickinson

$219.39

-5.09 (-2.27%)

BSX

Boston Scientific

$28.10

-0.49 (-1.71%)

MDT

Medtronic

$78.90

-1.91 (-2.36%)

SYK

Stryker

$153.39

-3.23 (-2.06%)

ZBH

Zimmer Biomet

$110.03

-1.81 (-1.62%)

CAH

Cardinal Health

$58.99

-1.57 (-2.59%)

MCK

McKesson

$137.88

-2.23 (-1.59%)

ABC

AmerisourceBergen

$75.33

0.06 (0.08%)

  • 15

    Nov

  • 28

    Nov

  • 05

    Dec

  • 14

    Dec

  • 18

    Mar

AMZN Amazon.com
$1,129.13

-3.75 (-0.33%)

11/10/17
NEED
11/10/17
UPGRADE
Target $79
NEED
Buy
Needham upgrades CVS to Buy despite potential Amazon threat
Needham analyst Kevin Caliendo upgraded CVS Health (CVS) to Buy from Hold with a $79 price target. The healthcare company closed yesterday up 3c to $69.02. The stock's risk/reward is favorable, especially if CVS is able to consummate the reported merger with Aetna (AET), Caliendo tells investors in a research note. The analyst puts a better than 50/50 chance of Amazon (AMZN) entering the pharmacy market, and sees CVS shares trading down to 9-10 times earnings in a worst case scenario. His best-case scenario has Amazon putting off a decision on pharmacy and CVS buying Aetna. Caliendo thinks CVS' multiple could expand to 14 times or more under his best case.
11/08/17
FBCO
11/08/17
NO CHANGE
FBCO
Amazon new furniture lines bring more problems for sector, says Credit Suisse
Credit Suisse analyst Seth Sigman notes that Amazon has introduced two new furniture lines - "Rivet" and "Stone & Beam," likely signaling an increased focus on the category. The analyst views the additions, associated aggressive delivery and return policies, and improved website experience as incremental risks to the category. Specifically, it validates concerns that pricing and delivery fees will continue to decline, dragging down margins, he contends.
11/08/17
DADA
11/08/17
NO CHANGE
Target $69
DADA
Buy
Applied Optoelectronics price target lowered to $69 from $86 at DA Davidson
DA Davidson analyst Mark Kelleher lowered his price target on Applied Optoelectronics (AAOI) to $69 following Q3 results, modeling weaker 40GB/100GB demand into his assumptions for both FY17 and FY18. Kelleher notes that the EPS beat came on the heels of a negative pre-announcement, as the company cited expectations of unexpected weakness from its largest customer Amazon (AMZN). The analyst is keeping his Buy rating on Applied Optoelectronics, saying the company remains well positioned to benefit from the growing dominance of "hyperscale" data centers.
11/08/17
UBSW
11/08/17
DOWNGRADE
Target $7
UBSW
Sell
Snap downgraded to Sell from Neutral at UBS
UBS analyst Eric Sheridan downgraded Snap (SNAP) to Sell and cut his price target for the shares to $7 from $12 following last night's Q3 results. The camera company is down 19%, or $2.88, to $12.24 in premarket trading. In a post-earnings research note titled "SNAP Crackle Flop," Sheridan says he finds it very likely that Snap will continue to struggle on "multiple fronts" in the coming 12 months. A redesigned app could bring opportunity but also platform disruption, Sheridan writes. He believes trying to scale its ad business amid "tepid" user growth while competing against Alphabet (GOOG), Facebook (FB) and Amazon.com (AMZN) is likely going to prove difficult for Snap.
BAX Baxter
$63.46

-1.935 (-2.96%)

10/27/17
10/27/17
DOWNGRADE

Hold
LeMaitre downgraded to Hold on slowing growth at Benchmark
As previously reported, Benchmark analyst Raymond Myers downgraded LeMaitre (LMAT) to Hold from Buy noting that is growth has slowed from its prior "unsustainable" pace and he sees some operational challenges. In the wake of the "unexpected" mid-2016 support from Baxter's (BAX) competitive recall, he anticipates tougher 2017 comparisons, he tells investors.
07/11/17
BMOC
07/11/17
UPGRADE
BMOC
Outperform
Baxter upgraded on valuation, outlook at BMO Capital
As noted earlier, BM Capital upgraded Baxter to Outperform from Market Perform. Analyst Joanne.Wuensch upgraded the stock based on valuation and her belief that it "will raise 2017 guidance, and meaningfully increase 2020 operating margin guidance." She also expects its operating margin to continue to rise and expects that its "above peer execution will continue." .Target to $70 from $55.
08/17/17
SBSH
08/17/17
INITIATION
Target $63
SBSH
Neutral
Baxter initiated with a Neutral at Citi
Citi analyst Amit Hazan started Baxter International with a Neutral rating and $63 price target. The analyst believes further margin improvements will be more modest than the past.
10/13/17
MSCO
10/13/17
NO CHANGE
MSCO
Underweight
Baxter impact from Puerto Rico better than some had feared, says Morgan Stanley
Morgan Stanley analyst David Lewis noted that Baxter provided more details on its impact from the disaster in Puerto Rico, stating that he gets the sense production levels are currently still well below 50% of capacity, but may be fully restored to normal capacity by year end. The analyst, who estimate about a 1% headwind to sales and 4c headwind to EPS for the quarter, said the impact appears manageable and better than some had feared. However, Lewis maintains an Underweight rating on Baxter shares.
BDX Becton Dickinson
$219.39

-5.09 (-2.27%)

10/24/17
WELS
10/24/17
NO CHANGE
Target $235
WELS
Outperform
Becton Dickinson price target raised to $235 from $225 at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen raised his price target for Becton Dickinson to $235 from $225 on valuation. The analyst also continues to expect positive results from the Lutonix below-the-knee trial in 2H17, and continues to see an over 50% probability that the Lutonix BTK trial will be positive and the indication could be FDA approved in 2018.He reiterates an Outperform rating on the shares.
09/22/17
09/22/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alibaba (BABA) initiated with an Overweight at Cantor. 2. Digital Realty (DLR) initiated with a Market Perform at William Blair. 3. PNM Resources (PNM) initiated with a Market Perform at Wells Fargo. 4. Madrigal Pharmaceuticals (MDGL) initiated with an Outperform at Evercore ISI. 5. Becton Dickinson (BDX) initiated with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/22/17
WELS
09/22/17
INITIATION
Target $225
WELS
Outperform
Becton Dickinson initiated with an Outperform at Wells Fargo
Wells Fargo analyst Larry Biegelsen started Becton Dickinson (BDX) with an Outperform rating and $225 price target. The analyst sees potential upside to C.R. Bard (BCR) acquisition accretion and believes any potential impact from the hurricanes in Q4 will be short-term.
11/01/17
PIPR
11/01/17
NO CHANGE
Target $213
PIPR
Overweight
Becton Dickinson 'swaying away' from beats and raises, says Piper Jaffray
Piper Jaffray analyst William Quirk says that post CareFusion, Becton Dickinson is "swaying away from a consistent beat-and-raise story." His remarks follow CareFusion international website checks that continued to suggest little new outside the U.S. product launches during the quarter. The analyst modestly lowered his Street-high Q4 revenue estimate and maintains an Overweight rating on Becton Dickinson with a $213 price target. He views the pending C.R. Bard (BCR) acquisition as "very attractive."
BSX Boston Scientific
$28.10

-0.49 (-1.71%)

10/24/17
10/24/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Boston Scientific (BSX) initiated with a Buy at Canaccord. 2. PQ Group (PQG) was initiated with a Buy at Nomura Instinet, Jefferies, Deutsche Bank, and Citi, an Overweight at KeyBanc, and a Neutral at JPMorgan and Goldman Sachs. 3. Tronox (TROX) initiated with an Overweight at JPMorgan. 4. Equinix (EQIX) initiated with a Buy at Deutsche Bank. 5. BioTelemetry (BEAT) initiated with a Buy at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/24/17
ADAM
10/24/17
INITIATION
Target $36
ADAM
Buy
Boston Scientific initiated with a Buy at Canaccord
Canaccord analyst Jason Mills initiated Boston Scientific with a Buy rating, citing is free cash flow and relative valuation. He believes the company is primed to deliver top and bottom-line growth above its peer group over the next few years helped by its compelling portfolio of differentiated products. Mills has a Street-high price target of $36 on Boston Scientific shares.
10/09/17
10/09/17
NO CHANGE

Valuations in Medical Technology look more attractive, says RBC Capital
RBC Capital analyst Glenn Novarro says the recent pullback in Medical Technology stocks since Q2 earnings has eliminated the valuation gap relative to other S&P Health Care subsectors. The analyst recommends a "Buy Now" for Johnson & Johnson (JNJ) and "Buy on Weakness" for Abbott Laboratories (ABT) among diversified MedTech names. In Cardiovascular, Novarro says "Buy Now" for Edwards Lifesciences (EW) and "Buy on Weakness" for Boston Scientific (BSX). For Nuvasive (NUVA) and Wright Medical (WMGI), the analyst says management will cut guidance because of hurricane related revenue shortfalls, but the selloff over the past several weeks is already discounting those expectations.
10/04/17
NEED
10/04/17
NO CHANGE
NEED
Boston Scientific deal should increase market share, says Needham
Needham analyst Mike Matson believes that Boston Scientific's acquisition of Apama Medical will enable it to increase its market share and the growth rate of its Electrophysiology business. The analyst reiterates a Buy rating on the stock.
MDT Medtronic
$78.90

-1.91 (-2.36%)

10/10/17
NEED
10/10/17
NO CHANGE
Target $94
NEED
Buy
Medtronic shares remain attractive despite hurricane impact, says Needham
Needham analyst Mike Matson lowered his price target on Medtronic to $94 from $95 to account for about $250M estimated negative impact from Puerto Rico manufacturing disruption due to Hurricane Maria. However, the analyst views the impact as temporary, maintaining his Buy rating given the large discount in stock price that Matson sees relative to peers. He also notes that reports of the company's "product cycle demise have been greatly exaggerated" and remains confident that Medtronic can sustain a mid-single digit revenue growth rate.
10/10/17
BMOC
10/10/17
NO CHANGE
Target $89
BMOC
Outperform
BMO sees $250M impact on Medtronic from hurricane manufacturing disruption
BMO Capital analyst Joanne Wuensch lowered her price target for Medtronic to $89 from $92, modeling a $250M impact on manufacturing in Puerto Rico resulting from Hurricane Maria. Wuensch notes that most of the impact will occur in Q2 of FY18, also lowering her EPS target for the year to $4.63 from $4.78. The analyst kept her Outperform rating on the stock.
10/16/17
SBSH
10/16/17
NO CHANGE
Target $359.33
SBSH
Buy
TransEnterix not 'in the same league' as Intuitive Surgical, says Citi
Citi analyst Amit Hazan believes Friday's FDA approval of TransEnterix's (TRXC) Senhance Surgical Robotic System should be viewed far less in the context of a competitive threat to Intuitive Surgical's (ISRG) da Vinci and more of another sign that the FDA has "eased its bar" for approval. The TransEnterix Senhance system is "at least currently not in the same league as da Vinci," Hazan tells investors in a research note titled "Intuitive's First US Competitor Arrives, Sort Of." He admits, however, that Intuitive is increasingly likely to see new competition, from Medtronic (MDT) first and then Johnson & Johnson's (JNJ) joint venture "much later," on time or earlier than expected. Hazan still expects Intuitive to dominate, however, and keeps a Buy rating on the shares. The stock sold off 3% in after-hours trading on Friday following TransEnterix's announcement.
10/09/17
10/09/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Humana (HUM) downgraded to Neutral from Overweight at JPMorgan with analyst Gary Taylor saying insider sales and the August board appointment render it unlikely that acquisition discussions are yet occurring. 2. Viacom (VIAB) downgraded to Sell from Neutral at Citi with analyst Jason Bazinet saying as media and cable companies jockey "for self-preservation," Charter Communications (CHTR) will likely drop, or significantly curtail, distribution of Viacom's content. 3. PTC Therapeutics (PTCT) downgraded to Underweight from Neutral at JPMorgan with analyst Anupam Rama saying the company's valuation remains at near pre-FDA Advisory Committee meetings levels, despite multiple "mixed / inconclusive / negative" updates recently. 4. Medtronic (MDT) downgraded to Market Perform from Outperform at Wells Fargo with analyst Larry Biegelsen saying a "lull" in major product cycles will drive below average organic sales growth over at least the next few quarters. 5. Symantec (SYMC) was downgraded to Underperform from Market Perform at Cowen and to Hold from Buy at Standpoint Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SYK Stryker
$153.39

-3.23 (-2.06%)

09/22/17
RBCM
09/22/17
NO CHANGE
RBCM
Growth investors should buy Stryker, says RBC Capital
RBC Capital analyst Glenn Novarro says that Stryker " will be the biggest share gainer in knees given its momentum in cementless and robotics." The analyst thinks that it will benefit in the near-term from Zimmer Biomet's (ZBH) supply issues. He recommends that growth investors buy Stryker.
10/31/17
OPCO
10/31/17
NO CHANGE
Target $156
OPCO
Outperform
Stryker price target raised to $156 from $148 at Oppenheimer
Oppenheimer analyst Steven Lichtman raised his price target for Stryker to $156 from $148 on higher estimates following quarterly results. The analyst reiterates an Outperform rating on the shares.
10/27/17
WELS
10/27/17
NO CHANGE
WELS
Stryker price target raised to $166 from $160 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised his price target on Styker to $166 from $160 after the company reported Q3 revenue that beat consensus estimates and slightly raised its FY17 organic sales growth to be in the 6.5%-7% range, up from previous guidance of "the low end" of that same range.
10/27/17
COWN
10/27/17
NO CHANGE
Target $166
COWN
Outperform
Stryker Q3 results solid despite challenges, says Cowen
Cowen analyst Joshua Jennings said Stryker reported solid Q3 results despite challenges from a Sage ship-hold and bad weather. The analyst said he is encouraged by the company's increased guidance as margins remain on track. Jennings reiterated his Outperform rating and raised his price target to $166 from $160 on Stryker shares.
ZBH Zimmer Biomet
$110.03

-1.81 (-1.62%)

11/07/17
RBCM
11/07/17
NO CHANGE
Target $125
RBCM
Outperform
Zimmer Biomet price target lowered to $125 from $140 at RBC Capital
RBC Capital analyst Glenn Novarro lowered his price target on Zimmer Biomet to $125 after Q3 earnings, saying the company continued to suffer from market share losses that were comparable to those of the first half as well the loss of business momentum in its S.E.T. division. Novarro is keeping his Outperform rating and urging investors to remain patient longer-term, with an update on CEO announcement before the end of the year and the re-inspection of the North Campus seen as catalysts toward regaining customer confidence and accelerating topline growth.
11/09/17
EDJN
11/09/17
UPGRADE
EDJN
Buy
Zimmer Biomet upgraded to Buy from Hold at Edward Jones
11/06/17
RHCO
11/06/17
NO CHANGE
Target $127
RHCO
Buy
Zimmer Biomet price target lowered to $127 from $136 at SunTrust
SunTrust analyst Bruce Nudell lowered his price target on Zimmer Biomet to $127 following Q3 results, citing expectations of lower assumed sales and gross margins. Nudell keeps his Buy rating, saying that while below-market performance in US knees segment was due in part to unit loss, the company expects its to improve toward the market growth rate with the resolution of supply constraints as well as the new Persona revision product sometime late in 2018.
11/09/17
11/09/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Square (SQ) upgraded to Buy from Neutral at Guggenheim. 2. T-Mobile (TMUS) upgraded to Buy from Hold at Deutsche Bank with analyst Matthew Niknam saying his unchanged price target of $65 represents 17% upside. 3. NetApp (NTAP) upgraded to Overweight from Underweight at Barclays with analyst Mark Moskowitz saying he sees NetApp benefiting from market share gains in all-flash arrays and easing cloud-related headwinds over the next 6-12 months. 4. Cabot Oil & Gas (COG) upgraded to Buy from Hold at Drexel Hamilton with analyst Robert Christensen citing news the U.S. Court of Appeals for the District of Columbia has denied an emergency motion to stay the Federal Energy Regulatory Commission's authorization of the company's Atlantic Sunrise pipeline project, allowing construction to recommence. 5. Zimmer Biomet (ZBH) upgraded to Buy from Hold at Edward Jones. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CAH Cardinal Health
$58.99

-1.57 (-2.59%)

10/27/17
JEFF
10/27/17
NO CHANGE
JEFF
Amazon licenses likely related to medical equipment, says Jefferies
News of Amazon.com's (AMZN) receipt of wholesale pharmacy licenses drove a sell-off yesterday in pharma supply chain stocks, Jefferies analyst Brian Tanquilut tells investors in a research note. Shares of AmerisourceBergen (ABC), Cardinal Health (CAH) and McKesson (MCK) fell yesterday in late afternoon trading. The analyst says that while the news strengthened investor fears about Amazon's entry into drug retailing, his due diligence indicates the licenses Amazon obtained are likely associated with its sale and distribution of medical equipment rather than prescription drugs. Tanquilut, however, recognizes that Amazon fears will overhang over prescription supply chain stocks in the near-term. He believes the impact to distributors from Amazon's professional medical device sales and distribution business remains difficult to assess.
10/10/17
10/10/17
NO CHANGE

Correction: Cowen maintains Market Perform rating on Cardinal Health
09/19/17
RBCM
09/19/17
INITIATION
RBCM
Sector Perform
Cardinal Health initiated with a Sector Perform at RBC Capital
RBC Capital analyst George Hill started coverage of Cardinal with a $72 price target and a Sector Perform rating.
10/10/17
COWN
10/10/17
UPGRADE
Target $189
COWN
Outperform
McKesson upgraded to Outperform from Market Perform at Cowen
Cowen analyst Charles Rhyee upgraded McKesson (MCK) to Outperform saying the transition towards differential specialty pricing will drive both earnings growth and multiple expansion. Distributor stocks, historically, fare very well coming out of a business model transition, Rhyee tells investors in a research note. He raised his price target for the shares to $189 from $176. The analyst this morning also upgraded AmerisourceBergen (ABC) to Outperform. Rhyee prefers both McKesson and AmerisourceBergen over Market Perform-rated Cardinal Health (CAH). He lowered his price target for the latter to $74 from $77.
MCK McKesson
$137.88

-2.23 (-1.59%)

11/09/17
FBCO
11/09/17
NO CHANGE
Target $130
FBCO
Underperform
McKesson price target lowered to $130 from $155 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright lowered her price target for McKesson to $130 from $155 on seemingly sustained industry challenges, including lackluster script volume and drug pricing challenges. The analyst reiterates an Underperform rating on the shares.
10/10/17
10/10/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Prudential (PRU) upgraded to Buy from Neutral at FBR Capital. 2. RBS (RBS) was upgraded to Neutral from Sell at Citi and to Neutral from Underperform at Credit Suisse. 3. Palo Alto Networks (PANW) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Keith Weiss saying he sees building traction across the company's portfolio of solutions and he views it as one of the best positioned vendors to execute on an integrated security platform story. 4. Illinois Tool Works (ITW) upgraded to Neutral from Underweight at JPMorgan with analyst Ann Duignan saying organic growth is likely to be better than forecast in the third quarter. 5. McKesson (MCK) upgraded to Outperform from Market Perform at Cowen with analyst Charles Rhyee saying the transition towards differential specialty pricing will drive both earnings growth and multiple expansion. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/01/17
NEED
11/01/17
NO CHANGE
Target $173
NEED
Buy
McKesson price target lowered to $173 from $178 at Needham
Needham analyst Kevin Caliendo lowered his price target on McKesson (MCK) to $173 despite a solid quarter, saying the positive results were overshadowed by Amazon (AMZN) receiving wholesale pharmacy licenses in 12 states. The analyst notes a 15% reversal in the stock price from its post-earnings high, also attributing the price target drop to changing investor sentiment and a a lowered terminal growth rate of 1%.
ABC AmerisourceBergen
$75.33

0.06 (0.08%)

10/10/17
COWN
10/10/17
UPGRADE
Target $98
COWN
Outperform
AmerisourceBergen upgraded to Outperform from Market Perform at Cowen
Cowen analyst Charles Rhyee upgraded AmerisourceBergen to Outperform saying the transition towards differential specialty pricing will drive both earnings growth and multiple expansion. Distributor stocks, historically, fare very well coming out of a business model transition, Rhyee tells investors in a research note. He raised his price target for the shares to $98 from $88.
11/06/17
NEED
11/06/17
NO CHANGE
Target $86
NEED
Buy
AmerisourceBergen price target lowered to $86 from $93 at Needham
Needham analyst Kevin Caliendo lowered his price target on AmerisourceBergen (ABC) to $86 following Q4 results and initial FY18 guidance. Caliendo says he questions expectations of 3%-5% profit growth amid the management's expectations of increased operating spending. The analyst keeps his Buy rating however, noting that the set-up for FY18 is still appealing, once year-end selling is finished and Amazon's (AMZN) plans on pharmaceutical distribution are disclosed.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.